Allergan plc (NYSE:AGN) Director Joseph H. Boccuzi bought 900 shares of the business’s stock in a transaction on Monday, March 5th. The stock was purchased at an average price of $143.42 per share, for a total transaction of $129,078.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Allergan plc (NYSE:AGN) opened at $157.28 on Monday. The firm has a market cap of $54,786.71, a price-to-earnings ratio of -11.72, a P/E/G ratio of 1.11 and a beta of 1.29. Allergan plc has a 12-month low of $142.81 and a 12-month high of $256.80. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 1.06.
Allergan (NYSE:AGN) last released its earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share for the quarter, beating analysts’ consensus estimates of $4.74 by $0.12. The business had revenue of $4.33 billion during the quarter, compared to the consensus estimate of $4.28 billion. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.43%. The firm’s revenue for the quarter was up 12.0% compared to the same quarter last year. During the same quarter last year, the firm earned $3.90 earnings per share. equities analysts forecast that Allergan plc will post 15.58 EPS for the current year.
A number of institutional investors have recently added to or reduced their stakes in the stock. Edgewood Management LLC grew its position in shares of Allergan by 24.3% in the 3rd quarter. Edgewood Management LLC now owns 4,445,924 shares of the company’s stock valued at $911,192,000 after acquiring an additional 869,248 shares during the period. Renaissance Technologies LLC grew its position in shares of Allergan by 1,049.7% in the 4th quarter. Renaissance Technologies LLC now owns 726,269 shares of the company’s stock valued at $118,803,000 after acquiring an additional 663,100 shares during the period. Baupost Group LLC MA grew its position in shares of Allergan by 21.9% in the 3rd quarter. Baupost Group LLC MA now owns 2,964,203 shares of the company’s stock valued at $607,513,000 after acquiring an additional 531,600 shares during the period. Asset Management One Co. Ltd. grew its position in shares of Allergan by 4,852.6% in the 3rd quarter. Asset Management One Co. Ltd. now owns 503,088 shares of the company’s stock valued at $103,108,000 after acquiring an additional 492,930 shares during the period. Finally, Millennium Management LLC grew its position in shares of Allergan by 277.7% in the 4th quarter. Millennium Management LLC now owns 651,755 shares of the company’s stock valued at $106,614,000 after acquiring an additional 479,174 shares during the period. 78.40% of the stock is owned by institutional investors and hedge funds.
AGN has been the topic of several analyst reports. Cantor Fitzgerald set a $191.00 target price on shares of Allergan and gave the stock a “hold” rating in a report on Tuesday, December 12th. Vetr downgraded shares of Allergan from a “hold” rating to a “sell” rating and set a $180.97 price objective for the company. in a research report on Monday, January 22nd. Bank of America increased their price objective on shares of Allergan from $208.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, February 7th. Deutsche Bank reissued a “buy” rating and set a $215.00 price objective on shares of Allergan in a research report on Tuesday, January 9th. Finally, ValuEngine downgraded shares of Allergan from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and fifteen have given a buy rating to the stock. Allergan currently has a consensus rating of “Buy” and a consensus target price of $225.03.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.